EEuropean Urology2/13/2026P0655 Intravesical Disitamab vedotin (RC48) for BCG-unresponsive high-risk non-muscle-Invasive bladder cancer: A multicenter Phase I trialX. Y. Chen·T. Lin·H. M. Hu·Z. D. Liu·P. Zhang·J. Huang·Q. Lv·M. Huang·S. J. JiangRead at European UrologyTagsBladder and Urothelial Cancer TreatmentsSurgery
